Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer

Sponsor
University of Southern California
Study ID
NCT01695057
Status
Withdrawn

Conditions

  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer
  • Triple-negative Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • vorinostat — DRUG
    Given PO
  • therapeutic conventional surgery — PROCEDURE
    Undergo surgery
  • laboratory biomarker analysis — OTHER
    Correlative studies

Study Details

This pilot clinical trial studies vorinostat before surgery in treating patients with triple-negative breast cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving enzyme inhibitor therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed

Key Dates

Start date
Oct 31, 2012
Status verified
Jan 2014
Primary completion
Oct 31, 2014
Completion
Oct 31, 2015

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (vorinostat and surgery)
    Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.

Primary Outcome Measure

Combined PR/ER response [ Time Frame: 21 days ]

Related Studies